Financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic license applications (BLA) Phase 2 data for izokibep in PsA presented at the 2022 European Alliance of Associations for Rheumatology Congress (EULAR) demonstrated differentiated efficacy across multiple endpoints including patient quality of life catalyzing program acceleration Combined with the Series B financing, ACELYRIN has secured more than a half billion dollars in committed capital in the last 12 months from a syndicate of blue-chip investors Strong financial position ensures the company has multi-year cash runway to further izokibep development in four late-stage clinical programs, explore additional indications, and aggressively pursue portfolio expansionLOS ANGELES, Sept. 13, 2022 /PRNewswire/ -- ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the delivery of transformative medicines in immunology, today announced a $300 million Series C financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic license applications (BLA). "The Phase 2 PsA data presented at EULAR 2022 validated our hypothesis that izokibeps unique inhibition of IL-17A through unprecedented high potency and small molecular size would enable differentiated efficacy, with greatest potential in aspects of disease historically difficult to treat with the much larger monoclonal antibodies," said Shao-Lee Lin, MD, PhD, co-founder and CEO, ACELYRIN. These results led us to accelerate planned Phase 3 development for PsA and AxSpA two diseases where enthesitis plays a key role creating significant value for patients through the potential for earlier access to izokibep. "The team at ACELYRIN are world-leading drug developers, having previously brought to millions of patients several of the most successful and impactful immunology treatments available," said Dan Becker, MD, PhD, managing director, Access Biotechnology. Under an exclusive licensing arrangement with Affibody AB, ACELYRIN holds global development and commercialization rights to izokibep, including in the United States, European Union, and Japan (excluding select Asian countries).